Table 1.
Clinical, pathological, and follow-up data of all the included patients. Comparative analysis between MI-FTC and WI-FTC.
| All patients | MI-FTC | WI-FTC | P value | |
|---|---|---|---|---|
| Patients | 130 | 66 | 64 | |
| Age (±SDa) (range) years | 51.1 ± 14.5 (18–88) | 50.0 ± 11.6 (28–76) | 52.3 ± 9.9 (18–88) | NS* |
| Male/female | 39/91 | 15/51 | 24/40 | NS* |
| Tumour size (± SDa) (range) mm | 28.9 ± 16.6 (5–100) | 23.1 ± 13.0 (5–70) | 35.1 ± 17.8 (11–100) | <0.001 |
| Distant metastasis at diagnosis | 4 | 1 | 3 | NS* |
| pT stage | ||||
| T1/T2/T3 | 36/63/31 | 27/33/6 | 9/30/25 | <0.001 |
| pT1 | 36 | 27 | 9 | <0.001 |
| pT2 | 63 | 33 | 30 | NS* |
| pT3 | 31 | 6 | 25 | <0.001 |
| pN stage | ||||
| NX/N0/N1 | 129/0/1 | 66/0/0 | 63/0/1 | NS* |
| pM stage | ||||
| M0/M1 | 126/4 | 65/1 | 61/3 | NS* |
| Multifocal disease | 4 | 2 | 2 | NS* |
| Microcarcinoma | 7 | 5 | 2 | NS* |
| HCC | 63 | 25 | 38 | <0.05 |
| Concomitant PTC | 21 | 15 | 6 | NS* |
| Follow-up yes/no | 117/13 | 62/4 | 55/9 | NS* |
| Follow-up (±SDa) (range) months | 103.9 ± 39.5 (17–182) | 95.5 ± 111.0 (17–174) | 104.5 ± 109.5 (27–182) | NS* |
| RAI/no RAI | 105/12 | 54/8 | 51/3 | NS* |
| Distant metastasis at follow-up | 3 | 0 | 3 | NS* |
SDa: standard deviation; NS*: not significant.